Zenyatta Ventures Ltd.; Drilling Continues at Albany Project; Mediation is On-going while Court Adjourned to June 15

Zenyatta Ventures Ltd. (ZEN: TSX Venture) (“Zenyatta” or “Company”) announces that the Motion for Injunction relief by Constance Lake First Nation (“CLFN”) in Ontario Superior Court was adjourned again until June 15th. In the meantime, Zenyatta, CLFN and Ontario (“Crown”) have been engaged in Mediation with Superior Court Justice Campbell while drilling continues at the Albany Project. If the parties do not reach a consensus during Mediation, the Motion for an Interim Injunction will be argued on June 15, 2011 before Justice Lederman in Ontario Superior Court.

Zenyatta remains committed to on-going good faith dialogue with the Crown and CLFN respecting the community's concerns but will defend its rights and interests. The Company’s Board and Management are optimistic that an agreement can be reached with CLFN in the near future.

To find out more on Zenyatta Ventures Ltd., please visit our website at www.zenyatta.ca or contact the Company at info@zenyatta.ca or Tel. 807-346-1660.

This news release may contain forward-looking statements and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the Company’s forward-looking statements and expectations. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

  • Share

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

To find out more about Zentek Ltd., please visit our website at www.zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR profile at www.sedar.com.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Tyler Dunn

Director, Marketing & Communications

tdunn@zentek.com

Subscribe for Updates

Interested in recieving press releases directly to your inbox? Subscribe to Zentek's mailing list for all the latest news.